GC
NVIV

Guggenheim Capital’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Guggenheim Capital’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-13
Closed -$987K – 2901
2017
Q1 		$987K Sell
13
-3
-19% -$242K ﹤0.01% 2110
2016
Q4 		$1.23M Buy
16
+7
+78% +$626K ﹤0.01% 2034
2016
Q3 		$1.21M Buy
+9
New +$1.12M ﹤0.01% 1976

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Guggenheim Capital's NVIV Position: Q2 2017 in Review

Guggenheim Capital sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2017, closing a stake of 13 shares — an estimated $987K sold.

Guggenheim Capital first reported a position in NVIV in Q3 2016 and held it in 3 quarters. The position peaked at $1.23M in Q4 2016. 37 funds tracked by Wall St. Rank hold NVIV as of Q2 2017.

  • Guggenheim Capital reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2017 after selling out during the quarter.
  • Guggenheim Capital sold 13 InVivo Therapeutics Holdings Corp shares in Q2 2017, an estimated $987K.
  • Guggenheim Capital first reported a position in InVivo Therapeutics Holdings Corp in Q3 2016 and held it in 3 quarters.
  • Guggenheim Capital's InVivo Therapeutics Holdings Corp position peaked at $1.23M in Q4 2016.
  • 37 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2017.

Based on Guggenheim Capital's 13F filing for Q2 2017, filed 14 Aug 2017.